
    
      We hope with this treatment improved antitumor efficacy without additional toxic side
      effects, while being shorter than 1.5 weeks of standard therapy. But this is an hypothesis we
      can not meet the current state of knowledge, which justifies this study.

      The main hypothesis is that this combination of reirradiation and Cetuximab give a relative
      gain of 15% complete response rate.
    
  